Results Underscore PRP Candidacy as a Disruptor of the Tumor MicroenvironmentMELBOURNE, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”) ...
FOLFIRINOX chemotherapy is feasible in selected elderly patients with pancreatic ductal adenocarcinoma, though toxicity ...
TEL AVIV, Israel, May 30, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today ...
A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 as a potential synthetic lethal marker for enhancing the efficacy of ATM ...
News Medical on MSN
CT-based quantification of tumor fibrosis guides chemotherapy in pancreatic cancer
On October 3, 2025, a multicenter team from Shenzhen University, Xiangya Hospital of Central South University, Zhujiang Hospital of Southern Medical University, Wuxi People's Hospital Affiliated to ...
RASolute 304 is anticipated to enroll approximately 500 patients with PDAC harboring oncogenic RAS mutations who have undergone resection and completed perioperative chemotherapy. The trial will ...
Individuals with chronic, untreated hepatitis C virus infection may be at greater risk for pancreatic ductal adenocarcinoma, ...
Now, researchers are turning to an unexpected source for early PDAC detection: faecal samples. While analysing poo might seem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback